Synopsis
HCV, a major cause of liver disease worldwide, is frequently resistant to the antiviral interferon-? therapy, being the only approved treatment available. It has been investigated recently that interleukin-8 (IL-8) induced by HCV partially inhibit the IFN-? therapy. Therefore we aimed to prospectively utilize the baseline IL-8 levels in the HCV infected serum and predict its role in sustained virological response (SVR) to IFN-? + ribavirin therapy, in chronic HCV patients. Fifteen normal volunteers and 110 HCV patients were enrolled in this study. Their baseline IL-8 levels were determined by ELISA and pre & post-treatment viral loads were recorded using qPCR. Different response rates to the therapy were observed and significant correlation was found between baseline IL-8 level and response to IFN therapy (P<0.01). Comparatively higher mean baseline IL-8 levels were observed in non-responders (2442.02 ±159.92 pg/ml), than the late (1009.31 ±45.31) and rapid (540.91 ±27.06 pg/ml) responders. Baseline IL-8 measurement should be used as a management tool before deciding the therapy, being involved in pathogenesis, persistence and resistance to antiviral therapy.
About the Author
Haji Akbar: Lecturer, Department of Biosciences, CIIT, Islamabad, Pakistan, Epx:-Molecular Biology; M Idrees Khan: PhD., Head of Molecular Virology Division,CEMB, PU,Lahore, Pakistan, Epx:- Molecular Virology; Khuram Shahzad: Graduate, Department of Animal Sciences,UIUC,USA. Exp:- Structural Bioinformatics and System Biology.
"About this title" may belong to another edition of this title.